Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis

Joint Bone Spine

Volumn 74, Issue 5, 2007, Pages 446-452

  Sellam, Jérémie ^a,c   Costedoat Chalumeau, Nathalie ^a   Amoura, Zahir ^a   Aymard, Guy ^a   Choquet, Sylvain ^a   Trad, Salim ^a   Vignes, Bénédicte Lebrun ^a   Hulot, Jean Sébastien ^a   Berenbaum, Francis ^b   Lechat, Philippe ^a   Cacoub, Patrice ^a   Ankri, Annick ^a   Mariette, Xavier ^c   Leblond, Véronique ^a   Piette, Jean Charles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Amyloidosis; Dexamethasone; Drug interactions; Fluindione; Multiple myeloma; Oral anticoagulants; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; DEXAMETHASONE; FLUINDIONE; MELPHALAN; METHYLPREDNISOLONE; THALIDOMIDE; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; AMYLOIDOSIS; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PROTHROMBIN TIME; PULMONARY HYPERTENSION; THROMBOEMBOLISM;

AGED; AMYLOIDOSIS; ANTICOAGULANTS; BLOOD COAGULATION; CREATININE; DEXAMETHASONE; DRUG SYNERGISM; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PATIENT SELECTION; PHENINDIONE; PROTHROMBIN TIME; WARFARIN;

EID: 35348864364     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.12.006     Document Type: Article

References (36)

1. Palladini G., Anesi E., Perfetti V., Obici L., Invernizzi R., Balduini C., et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 113 (2001) 1044-1046
2. Palladini G., Perfetti V., Obici L., Caccialanza R., Semino A., Adami F., et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103 (2004) 2936-2938
3. Gertz M.A., Lacy M.Q., Lust J.A., Greipp P.R., Witzig T.E., and Kyle R.A. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 16 (1999) 104-109
4. Strasser K., and Ludwig H. Thalidomide treatment in multiple myeloma. Blood Rev 16 (2002) 207-215
5. Clerc D., Fermand J.P., and Mariette X. Treatment of multiple myeloma. Joint Bone Spine 70 (2003) 175-186
6. Hausfater P., Costedoat-Chalumeau N., Amoura Z., Cacoub P., Papo T., Grateau G., et al. AL cardiac amyloidosis and arterial thromboembolic events. Scand J Rheumatol 34 (2005) 315-319
7. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 (1996) 423-428
8. Landefeld C.S., Rosenblatt M.W., and Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 87 (1989) 153-159
9. Levine M.N., Raskob G., Beyth R.J., Kearon C., and Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 287S-310S
10. Brigden M.L., Kay C., Le A., Graydon C., and McLeod B. Audit of the frequency and clinical response to excessive oral anticoagulation in an out-patient population. Am J Hematol 59 (1998) 22-27
11. Holbrook A.M., Pereira J.A., Labiris R., McDonald H., Douketis J.D., Crowther M., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165 (2005) 1095-1106
12. Wittkowsky A.K. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 3 (2003) 221-230
13. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204S-233S
14. Physician's Desk Reference. http://www.pdr.net Accessed 2005.
15. Costedoat-Chalumeau N., Amoura Z., Aymard G., Sevin O., Wechsler B., Cacoub P., et al. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med 132 (2000) 631-635
16. Costedoat N., Amoura Z., Leblond V., Cacoub P., Godeau P., and Piette J.C. [Vitamin K antagonist potentiation by oral dexamethasone in AL amyloidosis], (abstract). Rev Med Interne 22 (2001) 23s
17. Begg E.J., Atkinson H.C., and Gianarakis N. The pharmacokinetics of corticosteroid agents. Med J Aust 146 (1987) 37-41
18. Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., et al. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18 (1990) 595-606
19. Pichard L., Fabre I., Daujat M., Domergue J., Joyeux H., and Maurel P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes. Mol Pharmacol 41 (1992) 1047-1055
20. Hylek E.M., Heiman H., Skates S.J., Sheehan M.A., and Singer D.E. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 279 (1998) 657-662
21. Mahe I., Bertrand N., Drouet L., Simoneau G., Mazoyer E., Bal dit Sollier C., et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol 59 (2005) 371-374
22. Toth G.G., Kloosterman C., Uges D.R., and Jonkman M.F. Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit 21 (1999) 532-535
23. Mentre F., Pousset F., Comets E., Plaud B., Diquet B., Montalescot G., et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharmacol Ther 63 (1998) 64-78
24. Aymard G., Legrand M., Comets E., Mentre F., and Diquet B. Rapid and simple micromethod for the quantification of fluindione in human plasma using high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 707 (1998) 169-173
25. Chan K., and Woo K.S. Determination of warfarin in human plasma by high performance liquid chromatography. Methods Find Exp Clin Pharmacol 10 (1988) 699-703
26. Crowther M.A., Julian J., McCarty D., Douketis J., Kovacs M., Biagoni L., et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 356 (2000) 1551-1553
27. Kaufman M. Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. Mult Scler 3 (1997) 248-249
28. Rettie A.E., Korzekwa K.R., Kunze K.L., Lawrence R.F., Eddy A.C., Aoyama T., et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5 (1992) 54-59
29. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M., et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29 (2001) 242-251
30. Gerbal-Chaloin S., Daujat M., Pascussi J.M., Pichard-Garcia L., Vilarem M.J., and Maurel P. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 277 (2002) 209-217
31. Salphati L., and Benet L.Z. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers. Biochem Pharmacol 55 (1998) 387-395
32. Romiti N., Tramonti G., and Chieli E. Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol 183 (2002) 83-91
33. Mei Q., Richards K., Strong-Basalyga K., Fauty S.E., Taylor A., Yamazaki M., et al. Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2. J Pharm Sci 93 (2004) 2488-2496
34. Yood R.A., Skinner M., Rubinow A., Talarico L., and Cohen A.S. Bleeding manifestations in 100 patients with amyloidosis. JAMA 249 (1983) 1322-1324
35. Somer T. Rheology of paraproteinaemias and the plasma hyperviscosity syndrome. Baillieres Clin Haematol 1 (1987) 695-723
36. Torn M., Bollen W.L., van der Meer F.J., van der Wall E.E., and Rosendaal F.R. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 165 (2005) 1527-1532